Nirosen Vijiaratnam

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

Ruth Brauer, Li Wei, Tiantian Ma et al. · Brain · 2020 · 228 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The Impact of Type 2 Diabetes in Parkinson's Disease

Dilan Athauda, James R. Evans, Anna I. Wernick et al. · Movement Disorders · 2022 · 128 citations · Full text

Medicine, Neurology, Neuroscience +13

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Nirosen Vijiaratnam, Christine Girges, Grace Auld et al. · The Lancet · 2025 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

Nirosen Vijiaratnam, Christine Girges, Grace Auld et al. · BMJ Open · 2021 · 82 citations · Full text

Medicine, Neurology, Pharmacology +16

Neurofilament light levels predict clinical progression and death in multiple system atrophy

Elham Nikram, Alexandra Pérez‐Soriano, Carlo Wilke et al. · Brain · 2022 · 73 citations · Full text

Life Sciences, Neurology, Neuroscience +16